Posted on

Lenvatinib [4 mg/10 mg capsule] for the treatment of advanced or unresectable hepatocellular cancer (HCC) among adults

Cycle 1 | Drugs

HTA Council Recommendation (as of 19 January 2026)

As a final recommendation, the HTA Council recommends the government financing of Lenvatinib [4 mg/10 mg capsule] as first-line treatment for adults diagnosed with advanced or unresectable HCC who are not candidates for immunotherapy and/or
anti-VEGF.

Relevant Information

  • Status: With Final HTA Council Recommendation and SOH Decision
  • Topic Assignment: Internal Assessment
  • Policy Question: Should lenvatinib [4 mg/10 mg capsule] for the treatment of advanced or unresectable hepatocellular cancer (HCC) among adults be funded by the government?
  • Secretary of Health Decision: Approved as of 06 May 2026

Evidence and Relevant Documents

Back to Assessments Page